Metal coordinated compositions
First Claim
Patent Images
1. A metal coordination complex of a biologically active moiety and a metal, wherein:
- the biologically active moiety is selected from the group consisting of Zanamivir, Montelukast, Epoetin, Methotrexate, Hydralazine, Carbergoline, Gentamycin, Tobramycin, Acarbose, interference ribonucleic acid (iRNA), Atorvastatin, Lansoprazole, Losartan, Olanzapine, Gabapentin, Pemetrexed, Tenofovir, and derivatives thereof; and
wherein the metal is selected from the group consisting of aluminum, bismuth, calcium, copper, iron, magnesium, silicon, and zinc;
provided that the complex does not include a lansoprazole-Cu (II)-eosin.
0 Assignments
0 Petitions
Accused Products
Abstract
A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.
47 Citations
29 Claims
-
1. A metal coordination complex of a biologically active moiety and a metal, wherein:
-
the biologically active moiety is selected from the group consisting of Zanamivir, Montelukast, Epoetin, Methotrexate, Hydralazine, Carbergoline, Gentamycin, Tobramycin, Acarbose, interference ribonucleic acid (iRNA), Atorvastatin, Lansoprazole, Losartan, Olanzapine, Gabapentin, Pemetrexed, Tenofovir, and derivatives thereof; and wherein the metal is selected from the group consisting of aluminum, bismuth, calcium, copper, iron, magnesium, silicon, and zinc; provided that the complex does not include a lansoprazole-Cu (II)-eosin. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 24, 25)
-
-
10. A method of modulating properties of a biologically active moiety comprising:
-
forming a metal coordination complex of the biologically active moiety with a metal; wherein the biologically active moiety is selected from the group consisting of Zanamivir, Montelukast, Epoetin, Methotrexate, Hydralazine, Carbergoline, Gentamycin, Tobramycin, Acarbose, iRNA, Atorvastatin, Lansoprazole, Losartan, Olanzapine, Gabapentin, Pemetrexed, Tenofovir, and derivatives thereof; and wherein the metal is selected from the group consisting of aluminum, bismuth, calcium, copper, iron, magnesium, silicon, and zinc; provided that the complex does not include a lansoprazole-Cu (II)-eosin. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 19, 23)
-
-
20. A metal coordination complex of a biologically active moiety and a metal, wherein:
-
the biologically active moiety is selected from the group consisting of Zanamivir, Montelukast, Epoetin, Methotrexate, Hydralazine, Carbergoline, Gentamycin, Tobramycin, Acarbose, and derivatives thereof; and wherein the metal is selected from the group consisting of aluminum, bismuth, calcium, copper, iron, magnesium, silicon, and zinc. - View Dependent Claims (21, 22)
-
-
26. A metal coordination complex of a biologically active moiety and a metal, wherein:
-
the biologically active moiety is selected from the group consisting of;
Enalapri, Ramipril, and derivatives thereof; andwherein the metal is selected from the group consisting of;
aluminum, bismuth, calcium, iron, magnesium, silicon, and zinc.
-
-
27. A method of modulating properties of a biologically active moiety comprising:
-
forming a metal coordination complex of the biologically active moiety with a metal; wherein the biologically active moiety is selected from the group consisting of;
Enalapri, Ramipril, and derivatives thereof; andwherein the metal is selected from the group consisting of;
aluminum, bismuth, calcium, iron, magnesium, silicon, and zinc.
-
-
28. A metal coordination complex of a biologically active moiety and a metal, wherein:
-
the biologically active moiety is selected from the group consisting of;
Metronidazole and derivatives thereof; andwherein the metal is selected from the group consisting of;
aluminum, bismuth, calcium, iron, magnesium, and silicon.
-
-
29. A method of modulating properties of a biologically active moiety comprising:
-
forming a metal coordination complex of the biologically active moiety with a metal; wherein the biologically active moiety is selected from the group consisting of;
Metronidazole and derivatives thereof; andwherein the metal is selected from the group consisting of;
aluminum, bismuth, calcium, iron, magnesium, and silicon.
-
Specification